Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Cadrenal Therapeutics, Inc. issued 414,748 shares of Common Stock of warrant to certain investors named on the signature pages for $10.60 per share.
- Security
- warrant
- Shares
- 414,748 shares of Common Stock
- Purchaser
- certain investors named on the signature pages
- Consideration
- $10.60 per share
Exact text from the filing
attached as Exhibit 4.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Terms of the Common Warrants The Common Warrants have an exercise price of $10.60 per share. The shares of Common Stock issuable upon the exercise of the Common Warrants are referred to as the “Common Warrant Shares.” The Common Warrants are
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Cadrenal Therapeutics, Inc. issued 207,374 shares of common stock to certain investors named on the signature pages for $10.85 per share.
- Security
- common stock
- Shares
- 207,374 shares
- Purchaser
- certain investors named on the signature pages
- Consideration
- $10.85 per share
Exact text from the filing
private placement, unregistered warrants (the “Common Warrants”) to purchase up to 414,748 shares of Common Stock (collectively, the “Offering”). The offering price per Share is $10.85. The Shares are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-277835) (the “Registration Statement”), a base prospectus included
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Cadrenal Therapeutics, Inc. entered into Purchase Agreement with certain investors named on the signature pages thereto valued at approximately $2.2 million (effective 2025-12-15).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors named on the signature pages thereto
- Value
- approximately $2.2 million
- Effective
- 2025-12-15
Exact text from the filing
On December 15, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named on the signature pages thereto.
View on SEC.gov